A pharmaceutical company listed on the Hong Kong stock exchange for over three years announced its official delisting from the exchange, becoming the largest privatization trade in the medical sector completed in Hong Kong's capital markets in the past decade. On July 5th, Sino Biopharmaceutical Limited (hereafter referred to as 'Sino Biopharm') announced the completion of the privatization trade process and has officially been delisted from the Hong Kong Stock Exchange. The valuation of this trade is approximately 11.8 billion Hong Kong dollars (equivalent to about 11 billion RMB), which is the largest private acquisition trade completed in the Greater China region by private equity funds over the past three years. It is also the largest privatization transaction completed in the medical sector of Hong Kong's capital markets in the past decade. Sino Biopharm announced the privatization news when it released its 2023 financial report on March 28th of this year. According to the announcement at that time, Sino Biopharm's controlling shareholder, Defoe Capital, issued a privatization offer as the offeror on March 28th, 2024, and the delisting cancellation price was 18.8 Hong Kong dollars, which is the same as the issuing price when it went public on March 3rd, 2021. It is worth noting that this year, in addition to Sino Biopharm, many other Hong Kong-listed healthcare companies such as China Traditional Chinese Medicine (0570.HK) and Henlius (2696.HK) have also announced their delisting.